173 related articles for article (PubMed ID: 38200140)
1. Pharmacokinetic-pharmacodynamic analysis of drug liking blockade by buprenorphine subcutaneous depot (CAM2038) in participants with opioid use disorder.
Walsh SL; Comer SD; Zdovc JA; Sarr C; Björnsson M; Strandgården K; Hjelmström P; Tiberg F
Neuropsychopharmacology; 2024 May; 49(6):1050-1057. PubMed ID: 38200140
[TBL] [Abstract][Full Text] [Related]
2. Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial.
Walsh SL; Comer SD; Lofwall MR; Vince B; Levy-Cooperman N; Kelsh D; Coe MA; Jones JD; Nuzzo PA; Tiberg F; Sheldon B; Kim S
JAMA Psychiatry; 2017 Sep; 74(9):894-902. PubMed ID: 28655025
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic Evaluation of Once-Weekly and Once-Monthly Buprenorphine Subcutaneous Injection Depots (CAM2038) Versus Intravenous and Sublingual Buprenorphine in Healthy Volunteers Under Naltrexone Blockade: An Open-Label Phase 1 Study.
Albayaty M; Linden M; Olsson H; Johnsson M; Strandgården K; Tiberg F
Adv Ther; 2017 Feb; 34(2):560-575. PubMed ID: 28070862
[TBL] [Abstract][Full Text] [Related]
4. Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder.
Nasser AF; Greenwald MK; Vince B; Fudala PJ; Twumasi-Ankrah P; Liu Y; Jones JP; Heidbreder C
J Clin Psychopharmacol; 2016 Feb; 36(1):18-26. PubMed ID: 26650971
[TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetic Analysis Supports Initiation Treatment and Bridging from Sublingual Buprenorphine to Subcutaneous Administration of a Buprenorphine Depot (CAM2038) in the Treatment of Opioid Use Disorder.
Björnsson M; Acharya C; Strandgården K; Tiberg F
Clin Pharmacokinet; 2023 Oct; 62(10):1427-1443. PubMed ID: 37584841
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder.
Frost M; Bailey GL; Lintzeris N; Strang J; Dunlop A; Nunes EV; Jansen JB; Frey LC; Weber B; Haber P; Oosman S; Kim S; Tiberg F
Addiction; 2019 Aug; 114(8):1416-1426. PubMed ID: 31013390
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of a buprenorphine subcutaneous depot formulation (CAM2038) for once-weekly dosing in patients with opioid use disorder.
Haasen C; Linden M; Tiberg F
J Subst Abuse Treat; 2017 Jul; 78():22-29. PubMed ID: 28554599
[TBL] [Abstract][Full Text] [Related]
8. Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder With Fentanyl Use: A Post Hoc Analysis of a Randomized Clinical Trial.
Nunes EV; Comer SD; Lofwall MR; Walsh SL; Peterson S; Tiberg F; Hjelmstrom P; Budilovsky-Kelley NR
JAMA Netw Open; 2024 Jun; 7(6):e2417377. PubMed ID: 38916892
[TBL] [Abstract][Full Text] [Related]
9. Relationship between opioid cross-tolerance during buprenorphine stabilization and return to opioid use during buprenorphine dose tapering.
Greenwald MK; Sogbesan T; Moses TEH
Psychopharmacology (Berl); 2024 Jun; 241(6):1151-1160. PubMed ID: 38326506
[TBL] [Abstract][Full Text] [Related]
10. Population Pharmacokinetic Modeling After Repeated Administrations of RBP-6000, a New, Subcutaneously Injectable, Long-Acting, Sustained-Release Formulation of Buprenorphine, for the Treatment of Opioid Use Disorder.
Laffont CM; Gomeni R; Heidbreder C; Jones JP; Nasser AF
J Clin Pharmacol; 2016 Jul; 56(7):806-15. PubMed ID: 26479717
[TBL] [Abstract][Full Text] [Related]
11. Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial.
Lintzeris N; Dunlop AJ; Haber PS; Lubman DI; Graham R; Hutchinson S; Arunogiri S; Hayes V; Hjelmström P; Svedberg A; Peterson S; Tiberg F
JAMA Netw Open; 2021 May; 4(5):e219041. PubMed ID: 33970256
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Haight BR; Learned SM; Laffont CM; Fudala PJ; Zhao Y; Garofalo AS; Greenwald MK; Nadipelli VR; Ling W; Heidbreder C;
Lancet; 2019 Feb; 393(10173):778-790. PubMed ID: 30792007
[TBL] [Abstract][Full Text] [Related]
13. A population pharmacokinetic and pharmacodynamic modelling approach to support the clinical development of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid dependence.
Nasser AF; Heidbreder C; Gomeni R; Fudala PJ; Zheng B; Greenwald MK
Clin Pharmacokinet; 2014 Sep; 53(9):813-24. PubMed ID: 25015174
[TBL] [Abstract][Full Text] [Related]
14. Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial.
Lofwall MR; Walsh SL; Nunes EV; Bailey GL; Sigmon SC; Kampman KM; Frost M; Tiberg F; Linden M; Sheldon B; Oosman S; Peterson S; Chen M; Kim S
JAMA Intern Med; 2018 Jun; 178(6):764-773. PubMed ID: 29799968
[TBL] [Abstract][Full Text] [Related]
15. An injection depot formulation of buprenorphine: extended bio-delivery and effects.
Sigmon SC; Moody DE; Nuwayser ES; Bigelow GE
Addiction; 2006 Mar; 101(3):420-32. PubMed ID: 16499515
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of an injection depot formulation of buprenorphine: placebo comparison.
Sigmon SC; Wong CJ; Chausmer AL; Liebson IA; Bigelow GE
Addiction; 2004 Nov; 99(11):1439-49. PubMed ID: 15500597
[TBL] [Abstract][Full Text] [Related]
17. Rapid induction of transdermal buprenorphine to subcutaneous extended-release buprenorphine for the treatment of opioid use disorder.
Azar P; Schneiderman H; Barron H; Wong JSH; Meyer M; Newman-Azar D; Narimani M; Ignaszewski MJ; Mathew N; Mullen R; Krausz RM; Maharaj AR
Addict Sci Clin Pract; 2024 Jun; 19(1):50. PubMed ID: 38886826
[TBL] [Abstract][Full Text] [Related]
18. The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers.
Middleton LS; Nuzzo PA; Lofwall MR; Moody DE; Walsh SL
Addiction; 2011 Aug; 106(8):1460-73. PubMed ID: 21395892
[TBL] [Abstract][Full Text] [Related]
19. Novel Long-Acting Buprenorphine Medications for Opioid Dependence: Current Update.
Soyka M
Pharmacopsychiatry; 2021 Jan; 54(1):18-22. PubMed ID: 33212514
[TBL] [Abstract][Full Text] [Related]
20. Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices.
Greenwald M; Johanson CE; Bueller J; Chang Y; Moody DE; Kilbourn M; Koeppe R; Zubieta JK
Biol Psychiatry; 2007 Jan; 61(1):101-10. PubMed ID: 16950210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
